GlaxoSmithKline Pharmaceuticals informs about outcome of board meeting

13 May 2025 Evaluate
GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of the Company was held today, i.e. 13th May 2025 and transacted the following business: Pursuant to Regulation 33 of LODR the following documents are enclosed- Approved Audited Financial Statements & Results (Standalone and Consolidated) for the quarter & year ended 31st March 2025; Auditors Report for the year ended 31st March 2025; Statement of Assets and Liabilities; Certificate for unmodified opinion The Board has recommended a final dividend of Rs 42 per equity share on face value of Rs 10 each for the year ended 31st March 2025, subject to approval of members at 100th Annual General Meeting. 

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2455.25 -15.70 (-0.64%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×